Related Experiment Video
Updated: May 16, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Venlafaxine and neuropathic pain
Krystyna Cegielska-Perun1, Magdalena Bujalska-Zadrożny, Jan Tatarkiewicz
1Department of Pharmacodynamics, Medical University of Warsaw, Warsaw, Poland. kcegielska@wum.edu.pl
Pharmacology
|November 28, 2012
Summary
Venlafaxine (VFX) reduces pain in diabetic neuropathy by affecting both serotonin and noradrenaline systems. The noradrenergic system appears to be more crucial for this pain relief.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Diabetic neuropathic pain (DNP) is a debilitating condition.
- Venlafaxine (VFX), a serotonin and noradrenaline reuptake inhibitor, is used to manage pain.
- The precise mechanisms underlying VFX's antinociceptive effects in DNP require further elucidation.
Purpose of the Study:
- To investigate the neurochemical mechanisms of venlafaxine's antinociceptive effect in a diabetic neuropathic pain model.
- To determine the roles of noradrenergic and serotonergic systems in VFX's efficacy.
Main Methods:
- Utilized a diabetic neuropathic pain (DNP) model in rodents.
- Administered venlafaxine (VFX) both as a single dose and through chronic treatment.
- Investigated the involvement of specific neurotransmitter systems using antagonists: yohimbine (α(2)-adrenergic antagonist) and p-chloroamphetamine (serotonergic neurotoxin).
- Assessed the role of opioid pathways using naloxone (opioid antagonist).
Main Results:
- Venlafaxine (VFX) demonstrated a significant antihyperalgesic effect in the DNP model following both single and repeated administrations.
- The antihyperalgesic effect of VFX was significantly attenuated by yohimbine, indicating the involvement of the α(2)-adrenergic system.
- Pretreatment with p-chloroamphetamine reversed the antihyperalgesic effect of VFX, highlighting the contribution of serotonergic pathways.
- Naloxone did not reverse the effect of VFX, suggesting that opioid mechanisms are not primarily involved.
Conclusions:
- Both noradrenergic and serotonergic pathways are implicated in the antinociceptive action of venlafaxine (VFX) in diabetic neuropathic pain.
- The noradrenergic system appears to play a more dominant role in mediating the pain-relieving effects of VFX in this model.
Related Concept Videos
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...